eXoZymes Snags DOE Genesis Slot, Supercharging Its 9-Month AI Manufacturing Push

For growth-stage companies, landing a federal partnership is more than a trophy—it’s a catalyst. eXoZymes, already listed on NASDAQ, now gets access to DOE supercomputing and AI agents that would cost millions to build in-house. This injection of national-lab resources can turbocharge its product pipeline and send a strong signal to potential commercial partners and investors that its AI-driven biotech approach has serious backing.

eXoZymes Inc., a publicly traded pioneer in AI-enhanced enzyme engineering, has been selected for the U.S. Department of Energy’s inaugural Genesis Mission, a high-profile initiative designed to harness artificial intelligence for scientific breakthroughs. Announced on July 23, 2026, the nine-month project will see eXoZymes collaborate with Lawrence Berkeley National Laboratory (LBNL) researchers Dr. Edward Baidoo and Dr. Hector Garcia Martin to develop AI-powered digital twins for cell-free biomanufacturing. The award not only validates the company’s technology platform but also grants access to the DOE Genesis Mission Platform, a suite of advanced AI models, autonomous AI agents, and high-performance computing (HPC) infrastructure typically reserved for national laboratories and top-tier research institutions.

“

eXoZymes Inc., a publicly traded pioneer in AI-enhanced enzyme engineering, has been selected for the U.S.

This selection marks a strategic expansion for eXoZymes, moving beyond its core AI-driven enzyme design into AI-guided manufacturing optimization. By building digital twins—virtual replicas of physical bioprocesses—the company aims to simulate, predict, and accelerate the entire development cycle of cell-free biochemical production. Cell-free biomanufacturing, which uses enzymes outside living cells to convert feedstocks into high-value compounds like nutraceuticals and pharmaceuticals, is inherently complex due to the interplay of dozens of variables. Digital twins can slash the time-consuming trial-and-error experimentation, potentially cutting process development from years to months. This aligns with the Genesis Mission’s broader goal of reducing the design-build-test-learn cycle in biotechnology, a challenge that has historically kept many promising molecules stranded at lab scale.

For eXoZymes, the partnership is more than a research grant—it is an infrastructure windfall. The Genesis Mission Platform’s HPC resources will allow the company to run massive parallel simulations that would be economically unfeasible with in-house compute. The AI agents, likely specialized large language models or reinforcement learning systems, could autonomously propose experimental designs, interpret results, and refine models, creating a self-improving loop. This capability could dramatically lower the barrier to entry for bio-optimization, enabling the company to tackle a broader pipeline of products including novel enzymes for sustainable chemistry and next-generation therapeutics.

The market context is equally significant. Industrial biotechnology is undergoing a digital revolution, with AI-native startups attracting record funding. Major pharmaceutical companies are actively seeking alternatives to traditional cell-based fermentation, which often suffers from contamination risks, scale-up hurdles, and low yields. Cell-free systems promise faster, cleaner, and more controllable production, but their adoption has been slow due to the sheer complexity of optimization. By demonstrating a working AI-driven digital twin within a federal project, eXoZymes could position itself as a first mover in the emerging category of “AI-manufactured biologics,” potentially attracting partnerships with large pharma and contract manufacturing organizations.